Pancreatic Cancer Research

ResearcherEndeavor HealthActive in the last 2 years

Marina Talamonti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3070-4071; OpenAlex author ID A5046567040. Sources: OpenAlex.

Their work

Papers
16 (first author 7, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 16

  1. Modern Treatment Strategies for Borderline Resectable Pancreatic Cancer. First author DOI 10.1007/978-3-031-61238-1_4↗
  2. Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the m… Co-author DOI 10.1002/jso.27135↗
  3. Pancreatic cancer thromboembolic outcomes: rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery. Last author DOI 10.23736/s0392-9590.19.04127-0↗
  4. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. First author DOI 10.1002/jso.24872↗
  5. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? First author DOI 10.1016/j.surg.2017.09.022↗
  6. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  7. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. First author DOI 10.1016/j.amjsurg.2016.11.039↗
  8. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  9. A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer. First author DOI 10.1007/s11605-015-2957-2↗
  10. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. First author DOI 10.1016/j.surg.2016.07.033↗
  11. Pancreatic cancer and FOLFIRINOX: a new era and new questions. First author DOI 10.1002/cam4.433↗
  12. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3398↗
  13. CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Last author DOI 10.1097/coc.0b013e318280d5f0↗
  14. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000378↗
  15. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Co-author DOI 10.1007/s11605-012-2064-6↗
  16. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Co-author DOI 10.1136/gutjnl-2011-300821↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dominic J. Vitello · 1 shared paper, 2024 · strength 0.46
  2. Robert Marsh · 7 shared papers, 2014–2018 · strength 0.44
  3. David J. Bentrem · 8 shared papers, 2012–2018 · strength 0.41
  4. Marshall S. Baker · 6 shared papers, 2014–2018 · strength 0.38
  5. Richard A. Prinz · 5 shared papers, 2014–2018 · strength 0.31
  6. Kevin King Roggin · 3 shared papers, 2017–2018 · strength 0.21
  7. Olga Kantor · 3 shared papers, 2016–2017 · strength 0.19
  8. Melissa Ellen Hogg · 1 shared paper, 2023 · strength 0.18
  9. Divya Sood · 1 shared paper, 2023 · strength 0.18
  10. Sung Hoon Choi · 1 shared paper, 2023 · strength 0.18
  11. Hedy Lee Kindler · 3 shared papers, 2016–2018 · strength 0.18
  12. Waseem Lutfi · 2 shared papers, 2016–2017 · strength 0.13
  13. Matthew H. G. Katz · 2 shared papers, 2015–2016 · strength 0.12
  14. Joseph M. Herman · 2 shared papers, 2015–2016 · strength 0.12
  15. Alan Paul Venook · 2 shared papers, 2016–2018 · strength 0.10
  16. Jen Jen Yeh · 2 shared papers, 2015–2018 · strength 0.10
  17. Luis A. Diaz Quintero · 1 shared paper, 2019 · strength 0.10
  18. Jeffrey B. Matthews · 1 shared paper, 2018 · strength 0.07
  19. Mitchell C. Posner · 1 shared paper, 2018 · strength 0.07
  20. Daniel V.T. Catenacci · 1 shared paper, 2018 · strength 0.07
  21. Blasé N. Polite · 1 shared paper, 2018 · strength 0.07
  22. Nicholas R. Suss · 1 shared paper, 2018 · strength 0.07
  23. Nicole F. Neel · 1 shared paper, 2018 · strength 0.06
  24. Federico Innocenti · 1 shared paper, 2018 · strength 0.06
  25. Mark J. Ratain · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.